Basit öğe kaydını göster

Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

dc.contributor.authorGresty, C.
dc.contributor.authorHussain, M.
dc.contributor.authorOlmos, D.
dc.contributor.authorThiery-Vuillemin, A.
dc.contributor.authorTwardowski, P.
dc.contributor.authorRoubaud, G.
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorKang, J.
dc.contributor.authorBurgents, J.
dc.contributor.authorCorcoran, C.
dc.contributor.authorAdelman, C. A.
dc.contributor.authorde Bono, J. S.
dc.contributor.authorMateo, J.
dc.contributor.authorFizazi, K.
dc.contributor.authorSaad, F.
dc.contributor.authorShore, N.
dc.contributor.authorSandhu, S.
dc.contributor.authorChi, K. N.
dc.contributor.authorSartor, O.
dc.contributor.authorAgarwal, N.
dc.date.accessioned2021-03-02T17:07:02Z
dc.date.available2021-03-02T17:07:02Z
dc.identifier.citationde Bono J. S. , Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., Chi K. N. , Sartor O., Agarwal N., Olmos D., et al., "Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations", ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31
dc.identifier.othervv_1032021
dc.identifier.otherav_b5a6dc63-ed4a-4d0f-8310-70a12e25beff
dc.identifier.urihttp://hdl.handle.net/20.500.12627/3570
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2020.08.870
dc.language.isoeng
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.titleFinal overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
dc.typeBildiri
dc.contributor.departmentRoyal Marsden NHS Foundation Trust , ,
dc.identifier.volume31
dc.contributor.firstauthorID2287020


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster